RxDoctor Payments Data

Anja Mejia

Family · Bakersfield, CANPI 1073198347

Payments from drug & device makers

$578in general payments, 2019–2025

Across 21 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$124
  • AstraZeneca$114
  • Novo Nordisk$107
  • Revance Therapeutics, Inc.$56
  • Biosense Webster, Inc.$43
  • Medtronic$34
  • plus $100 from 4 others

What the payments were for

  • Food & beverage$578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$578 in reported general payments places this provider in the 60th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$44,769
Medicare patients
149
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$61,588
JardianceEmpagliflozin49$28,597
MounjaroTirzepatide24$23,826
FarxigaDapagliflozin Propanediol40$20,661
JanuviaSitagliptin Phosphate27$16,670
TradjentaLinagliptin27$13,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,833
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,657
XareltoRivaroxaban17$9,256
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,953
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$4,948
Qvar RedihalerBeclomethasone Dipropionate15$3,473
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,033
Albuterol Sulfate HfaAlbuterol Sulfate73$1,959
Gabapentin76$976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$61,58869 claims
AstraZenecaFarxiga, Breztri Aerosphere$114$31,31858 claims
GSKTrelegy Ellipta, Anoro Ellipta$124$16,78132 claims
Johnson & JohnsonXarelto$22$9,25617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,634 family providers in California.

Other family in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →